brachyury vaccine

Brachyury vaccine is a **non-specific umbrella term** for investigational therapeutic cancer vaccines designed to induce antitumor immunity against **brachyury**, a transcription factor implicated in epithelial-to-mesenchymal transition, metastasis, and treatment resistance and highly expressed in chordoma and several epithelial cancers. The term most commonly refers to at least two distinct products: **MVA-BN-brachyury-TRICOM**, a recombinant poxviral prime-boost vaccine developed by Bavarian Nordic with the National Cancer Institute, and **GI-6301**, a heat-killed recombinant *Saccharomyces cerevisiae* yeast-based vaccine developed by GlobeImmune. These agents are cancer immunotherapies rather than a single defined drug product, have mainly been studied in chordoma and other solid tumors, and have shown immunogenicity and acceptable safety but limited clinical efficacy to date.

Other names

brachyury vaccinebrachyury-targeted cancer vaccinebrachyury therapeutic cancer vaccine